Prognostic factors for response (CR) to salvage therapy and overall survival
| Characteristic . | No. of patients . | CR, n (%) . | P . | Overall survival . | P . | ||
|---|---|---|---|---|---|---|---|
| Median . | 6 mo, % . | 1 y, % . | |||||
| Age, y | |||||||
| < 50 | 41 | 10 (24) | 7 | 52 | 25 | ||
| 50-59 | 63 | 13 (21) | .28 | 4 | 41 | 23 | .11 |
| ≥ 60 | 88 | 12 (14) | 3 | 30 | 11 | ||
| Platelet, ×109/L | |||||||
| < 30 | 97 | 9 (9) | 3 | 31 | 12 | ||
| 30-50 | 35 | 6 (17) | .002 | 5 | 34 | 14 | .004 |
| 51-99 | 27 | 9 (33) | 7 | 52 | 33 | ||
| ≥ 100 | 33 | 11 (33) | 6 | 55 | 30 | ||
| WBC, ×109/L | |||||||
| < 1.0 | 40 | 4 (10) | 3 | 25 | 13 | ||
| 1.0-9.9 | 128 | 28 (22) | .21 | 6 | 48 | 23 | < .001 |
| ≥ 10.0 | 24 | 3 (13) | 2 | 8 | 4 | ||
| Marrow blast, % | |||||||
| < 20 | 40 | 9 (23) | 6 | 48 | 29 | ||
| 20-39 | 44 | 11 (25) | .03 | 7 | 52 | 23 | < .001 |
| 40-49 | 24 | 6 (25) | 4 | 38 | 8 | ||
| ≥ 50 | 60 | 4 (7) | 2 | 20 | 12 | ||
| Therapy related | |||||||
| Yes | 37 | 3 (8) | .1 | 3 | 30 | 14 | .12 |
| No | 155 | 32 (21) | 4 | 41 | 20 | ||
| Cytogenetics at Dx | |||||||
| Diploid/Y-/IM | 64 | 20 (31) | 6 | 48 | 27 | < .001 | |
| Intermediate | 38 | 8 (21) | .001 | 4 | 45 | 21 | |
| Unfavorable | 89 | 7 (8) | 3 | 29 | 11 | ||
| AHD | |||||||
| Yes | 107 | 12 (11) | .008 | 3 | 36 | 14 | .26 |
| No | 85 | 23 (27) | 5 | 42 | 24 | ||
| Salvage Rx | |||||||
| Combo − AC | 35 | 5 (14) | 6 | 49 | 14 | ||
| Combo + AC | 75 | 12 (16) | < .001 | 2 | 29 | 15 | .005 |
| Single agent | 60 | 5 (8) | 4 | 33 | 13 | ||
| AlloSCT | 22 | 13 (59) | 11 | 68 | 50 | ||
| Characteristic . | No. of patients . | CR, n (%) . | P . | Overall survival . | P . | ||
|---|---|---|---|---|---|---|---|
| Median . | 6 mo, % . | 1 y, % . | |||||
| Age, y | |||||||
| < 50 | 41 | 10 (24) | 7 | 52 | 25 | ||
| 50-59 | 63 | 13 (21) | .28 | 4 | 41 | 23 | .11 |
| ≥ 60 | 88 | 12 (14) | 3 | 30 | 11 | ||
| Platelet, ×109/L | |||||||
| < 30 | 97 | 9 (9) | 3 | 31 | 12 | ||
| 30-50 | 35 | 6 (17) | .002 | 5 | 34 | 14 | .004 |
| 51-99 | 27 | 9 (33) | 7 | 52 | 33 | ||
| ≥ 100 | 33 | 11 (33) | 6 | 55 | 30 | ||
| WBC, ×109/L | |||||||
| < 1.0 | 40 | 4 (10) | 3 | 25 | 13 | ||
| 1.0-9.9 | 128 | 28 (22) | .21 | 6 | 48 | 23 | < .001 |
| ≥ 10.0 | 24 | 3 (13) | 2 | 8 | 4 | ||
| Marrow blast, % | |||||||
| < 20 | 40 | 9 (23) | 6 | 48 | 29 | ||
| 20-39 | 44 | 11 (25) | .03 | 7 | 52 | 23 | < .001 |
| 40-49 | 24 | 6 (25) | 4 | 38 | 8 | ||
| ≥ 50 | 60 | 4 (7) | 2 | 20 | 12 | ||
| Therapy related | |||||||
| Yes | 37 | 3 (8) | .1 | 3 | 30 | 14 | .12 |
| No | 155 | 32 (21) | 4 | 41 | 20 | ||
| Cytogenetics at Dx | |||||||
| Diploid/Y-/IM | 64 | 20 (31) | 6 | 48 | 27 | < .001 | |
| Intermediate | 38 | 8 (21) | .001 | 4 | 45 | 21 | |
| Unfavorable | 89 | 7 (8) | 3 | 29 | 11 | ||
| AHD | |||||||
| Yes | 107 | 12 (11) | .008 | 3 | 36 | 14 | .26 |
| No | 85 | 23 (27) | 5 | 42 | 24 | ||
| Salvage Rx | |||||||
| Combo − AC | 35 | 5 (14) | 6 | 49 | 14 | ||
| Combo + AC | 75 | 12 (16) | < .001 | 2 | 29 | 15 | .005 |
| Single agent | 60 | 5 (8) | 4 | 33 | 13 | ||
| AlloSCT | 22 | 13 (59) | 11 | 68 | 50 | ||
CR indicates complete response; AlloSCT, allogeneic stem cell transplantation; Dx, diagnosis; AHD, antecedent hematologic disorder; and Rx, treatment.